Summary
GlobalData's clinical trial report, “Diabetic Peripheral Neuropathy Global Clinical Trials Review, H1, 2016" provides an overview of Diabetic Peripheral Neuropathy clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Peripheral Neuropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Companies Mentioned
Pfizer Inc.
Eli Lilly and Company
Nestle Health Science S.A.
Astellas Pharma Inc.
Grunenthal GmbH
ViroMed Co., Ltd.
Johnson & Johnson
Diablo Clinical Research, Inc.
Depomed, Inc.
C. H. Boehringer Sohn AG & Co. KG
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Diabetic Peripheral Neuropathy to Metabolic Disorders Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Diabetic Peripheral Neuropathy to Metabolic Disorders Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Diabetic Peripheral Neuropathy Therapeutics Clinical Trials 27
Prominent Drugs 28
Latest Clinical Trials News on Diabetic Peripheral Neuropathy 29
Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy 29
May 16, 2016: BioNevia and NeuroMax Announce Completion of Enrollment in Phase 2b Clinical Trial of BNV-222 29
May 11, 2016: Maxwell Biotech Venture Fund's Portfolio Company NeuroMax Announce Completion of Enrollment in Phase 2b Clinical Trial of BNV-222 30
Clinical Trial Profile Snapshots 31
Appendix 107
Abbreviations 107
Definitions 107
Research Methodology 108
Secondary Research 108
About GlobalData 109
Contact Us 109
Disclaimer 109
Source 110
List of Tables
Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Region, 2016* 6
Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
Proportion of Diabetic Peripheral Neuropathy to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016* 14
Diabetic Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Diabetic Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Diabetic Peripheral Neuropathy to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016* 17
Diabetic Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Diabetic Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Diabetic Peripheral Neuropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
List of Figures
Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
Proportion of Diabetic Peripheral Neuropathy to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016* 14
Diabetic Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Diabetic Peripheral Neuropathy Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Diabetic Peripheral Neuropathy to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016* 17
Diabetic Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Diabetic Peripheral Neuropathy Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Diabetic Peripheral Neuropathy Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Diabetic Peripheral Neuropathy Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Diabetic Peripheral Neuropathy Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
GlobalData Methodology 108
